⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.

NIVF — NewGenIvf Group Limited

Last scan (Sept. 28, 2026): price $0.56, RSI 22.37, relative volume 68.90x, MACD ⚪ No, score 60.00.

It's trading below its 200-day average, with an RSI of 22.37 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Today's volume is 68.9x average — well above normal activity, a sign of real interest. The analysts' average target price implies +22592.9% upside — one of the score's strongest signals. Today it holds rank #1 in the Penny group on Smart Scanner's upside + relative volume ranking.

back to scanner

Price chart

Price: $0.57 · RSI (14): 42.65 · Rel. volume: 1.47x · Breakout: No

You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.

What analysts say

NIVF

NewGenIvf Group Limited Healthcare · Medical Care Facilities

NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI,…

No data

No analyst breakdown available for NIVF.

Average target price: $127.08 (+22588.8% vs. current price) · range $127.08 – $127.08

Healthy Moderate Attention No data

Market cap $1.35M

Total market value of the company (price × shares outstanding).

P/E (trailing) N/A
?

P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.

Low: the market pays little for each dollar of earnings. Could be a value opportunity, or a sign the market expects little growth.

P/E (forward) 0.01
?

P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.

Same as P/E, using estimated future earnings.

PEG N/A
?

PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.

Not enough data (requires future growth estimates).

Debt/Equity 18.74%
?

Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.

Low leverage: conservative balance sheet, less risk if interest rates rise.

Net margin 209.03%
?

Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.

High margin: usually indicates a strong competitive advantage (brand, scale, technology).

Dividend N/A
?

Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.

Doesn't pay dividends: reinvests earnings into growth instead of distributing them.

Beta (risk) -0.04
?

Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).

Less volatile than the overall market (S&P 500 = 1.0).

General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.

💰 Financial Statements (last 3 quarters)

💰 Financial Statements (last 3 quarters)

Advertisement

What this chart shows

Third-party market data, for informational purposes. Not investment advice — read the disclaimer.